Oxford University and Moderna begin clinical trials of a vaccine designed to prevent cancer in people with Lynch syndrome, a hereditary condition associated with significantly increased risks of colorectal and ovarian cancers. The vaccine targets individuals who carry Lynch syndrome and therefore face higher lifetime risks of developing cancer in the colon and ovaries compared with the general population. The trial effort is presented as an attempt to shift cancer prevention from screening and early detection toward immunisation in a defined high-risk group. The reports describe the vaccine as being in early-stage testing and focus on the target patient population rather than providing detailed results. The sources agree on the partnership and the overall goal of reducing the incidence of cancer by inducing immune responses in Lynch syndrome patients. Specific trial locations, study phases, and timelines are not included in the provided excerpts.